Seungwoo Hong
YOU?
Author Swipe
View article: FASTKD5 processes mitochondrial pre-mRNAs at noncanonical cleavage sites
FASTKD5 processes mitochondrial pre-mRNAs at noncanonical cleavage sites Open
The first post-transcriptional step in mammalian mitochondrial gene expression, required for the synthesis of the 13 polypeptides encoded in mitochondrial DNA (mtDNA), is endonucleolytic cleavage of the primary polycistronic transcripts. E…
View article: Enhancing visible-light-driven photocatalysis of Pd- and Pt-doped WO<sub>3</sub> nanoparticles: the role of oxygen vacancies and bandgap narrowing
Enhancing visible-light-driven photocatalysis of Pd- and Pt-doped WO<sub>3</sub> nanoparticles: the role of oxygen vacancies and bandgap narrowing Open
The global energy demand has driven the development of efficient and cost-effective visible-light-activated photocatalysts for the synthesis of fine chemicals.
View article: Synthetic Control Over Oxygen Vacancy Density in Cobalt Oxide Nanoparticles and the Implications of Surface Imperfections on Catalysis
Synthetic Control Over Oxygen Vacancy Density in Cobalt Oxide Nanoparticles and the Implications of Surface Imperfections on Catalysis Open
View article: Empowering Visible-Light-Driven Photocatalysis of Pd- and Pt-Doped Wo3 Nanoparticles: Role of Oxygen Vacancies and Narrowed Bandgap
Empowering Visible-Light-Driven Photocatalysis of Pd- and Pt-Doped Wo3 Nanoparticles: Role of Oxygen Vacancies and Narrowed Bandgap Open
View article: Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy Open
View article: Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer
Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer Open
Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab. However, cetuximab is used only for patients possessing the wild-type oncoge…
View article: CCDC 2249403: Experimental Crystal Structure Determination
CCDC 2249403: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2249404: Experimental Crystal Structure Determination
CCDC 2249404: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2249401: Experimental Crystal Structure Determination
CCDC 2249401: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of FGFR3 or FGFR4 on the sensitivities of PHA665752-treated HCC cell lines.
View article: Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers, including human hepatocellular …
View article: Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of c-MET on phospho-MET and FGFR negative-HCC cell lines.
View article: Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Inhibition of cell growth and downstream signaling molecules of HCC cell lines by MET or pan-FGFR inhibitor.
View article: Supplementary Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
Supplementary Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells Open
Supplementary Data from p34SEI-1 Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-Jun-NH2-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
View article: Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Data from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers, including human hepatocellular …
View article: Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells Open
In this study, we describe a novel function of the p34SEI-1 protein, which is both an oncogenic protein and a positive regulator of the cell cycle. The p34SEI-1 protein was found to inhibit doxorubicin-induced senesce…
View article: Supplementary Figure 5 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 5 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Expression of phospho-Met and FGFR in TMAs of tumor samples from HCC patients.
View article: Supplementary Figure legend from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure legend from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Supplementary Figure legend
View article: Supplementary Table 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Table 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
The Hepatitis B (HBV) or C virus (HCV) infectious status on primary cancer cells
View article: Supplementary Figure legend from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure legend from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Supplementary Figure legend
View article: Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Inhibition of cell growth and downstream signaling molecules of HCC cell lines by MET or pan-FGFR inhibitor.
View article: Supplementary Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
Supplementary Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells Open
Supplementary Data from p34SEI-1 Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-Jun-NH2-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
View article: Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of FGFR3 or FGFR4 on the sensitivities of PHA665752-treated HCC cell lines.
View article: Supplementary Figure 5 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 5 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Expression of phospho-Met and FGFR in TMAs of tumor samples from HCC patients.
View article: Supplementary Figure 3 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 3 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of MET on the sensitivities of AZD4547-treated HCC cell lines.
View article: Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of c-MET on phospho-MET and FGFR negative-HCC cell lines.
View article: Supplementary Figure 3 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Figure 3 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
Effects of MET on the sensitivities of AZD4547-treated HCC cell lines.
View article: Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells
Data from p34<sup>SEI-1</sup> Inhibits Doxorubicin-Induced Senescence through a Pathway Mediated by Protein Kinase C-δ and c-<i>Jun</i>-NH<sub>2</sub>-Kinase 1 Activation in Human Breast Cancer MCF7 Cells Open
In this study, we describe a novel function of the p34SEI-1 protein, which is both an oncogenic protein and a positive regulator of the cell cycle. The p34SEI-1 protein was found to inhibit doxorubicin-induced senesce…
View article: Supplementary Table 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Supplementary Table 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity Open
The Hepatitis B (HBV) or C virus (HCV) infectious status on primary cancer cells
View article: Data from p34<sup>SEI-1</sup> Inhibits Apoptosis through the Stabilization of the X-Linked Inhibitor of Apoptosis Protein: p34<sup>SEI-1</sup> as a Novel Target for Anti–Breast Cancer Strategies
Data from p34<sup>SEI-1</sup> Inhibits Apoptosis through the Stabilization of the X-Linked Inhibitor of Apoptosis Protein: p34<sup>SEI-1</sup> as a Novel Target for Anti–Breast Cancer Strategies Open
The p34SEI-1 protein exerts oncogenic effects via regulation of the cell cycle, which occurs through a direct interaction with cyclin-dependent kinase 4. Such regulation can increase the survival of various types of tumor cells.…